Ribose-modified adenosine analogues as adenosine receptor agonists

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Cardiovascular Pharmacology

Background:

• Adenosine receptors are critical targets for modulating central nervous system and cardiovascular functions.
• (R)-N-(1-methyl-2-phenylethyl)adenosine (R-PIA) is a potent adenosine receptor agonist.
• Modifications at the N9 position of adenosine analogues can alter receptor binding and biological activity.

Purpose of the Study:

• To synthesize and characterize novel adenosine receptor agonists with modifications at the N9 position.
• To evaluate the binding affinity of these analogues to adenosine A1 and A2 receptors.
• To assess the in vivo central nervous system and cardiovascular effects of the synthesized compounds.

Main Methods:

• Synthesis of N9-modified analogues of (R)-N-(1-methyl-2-phenylethyl)adenosine (R-PIA).
• In vitro radioligand binding assays to determine affinity for adenosine A1 and A2 receptors.
• In vivo studies to evaluate behavioral and cardiovascular effects in animal models.

Main Results:

• Most N9-modified analogues exhibited poor affinity for adenosine receptors.
• Minor modifications at the C5' and C3' positions were essential for retaining potent receptor binding.
• Compounds with significant in vivo behavioral or cardiovascular effects generally displayed the highest adenosine receptor affinity.

Conclusions:

• The N9 position of R-PIA analogues is sensitive to structural modifications, with most changes leading to reduced receptor affinity.
• Specific minor modifications at C5' and C3' can preserve or enhance adenosine receptor binding.
• Adenosine receptor affinity correlates with observed in vivo central nervous system and cardiovascular activities, highlighting the therapeutic potential of carefully designed analogues.